2023-09-13 07:57:58 ET
(24/7 MARKET NEWS) – Mainz Biomed N.V. (NASDAQ:MYNZ) reported, this morning, positive topline results from its ColoFuture study, a multi-center international clinical trial assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert, the Company’s screening test for colorectal cancer (CRC), which is being commercialized across Europe and other international territories. In addition to reporting sensitivity for colorectal cancer of 94% with a specificity of 97% and a sensitivity for advanced adenoma of 81%, multiple novel mRNA biomarkers were identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense).
Mainz Biomed is trading at $4.22, up $0.56 (+15.30%), on 1.53M premarket shares traded.
Its 52-week range is $2.8394 to $9.6135. The resistance to $4.75 …
The post Mainz Biomed Reports 94% Sensitivity for Colorectal Cancer, with Specificity of 97%, and Advanced Adenoma Sensitivity of 81%, in ColoFuture Study appeared first on 24/7 Market News .
For further details see:
Mainz Biomed Reports 94% Sensitivity for Colorectal Cancer, with Specificity of 97%, and Advanced Adenoma Sensitivity of 81%, in ColoFuture Study